Provided by Tiger Trade Technology Pte. Ltd.

Oculis

13.18
+0.09500.73%
Post-market: 13.250.0700+0.53%19:30 EDT
Volume:150.39K
Turnover:1.97M
Market Cap:813.63M
PE:-7.68
High:13.25
Open:13.10
Low:12.87
Close:13.09
52wk High:34.48
52wk Low:10.52
Shares:61.73M
Float Shares:53.44M
Volume Ratio:0.86
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7151
EPS(LYR):-2.3888
ROE:-43.70%
ROA:-24.95%
PB:2.98
PE(LYR):-5.52

Loading ...

Oculis to Acquire Mitie in £3.1 Billion Deal, Sending Target's Shares Soaring 40%

Deep News
·
Jul 21

Mitie Shares Soar on $4.2 Billion Takeover by OCS

Dow Jones
·
Jul 21

Mitie Halts £100m Share Buyback After Recommended OCS Takeover Offer

TIPRANKS
·
Jul 21

Village Farms Unveils Super Toast Bites, a New Line of Cannabis-Infused Gummies

GlobeNewswire
·
Jul 14

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Jul 09

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

GlobeNewswire
·
Jul 02

Oculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch

TIPRANKS
·
Jul 02

Nordic Shares Gain; Oculis Holding Tops Leaders

Dow Jones
·
Jul 01

Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway

TIPRANKS
·
Jun 26

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Jun 16

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

GlobeNewswire
·
Jun 11

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

GlobeNewswire
·
Jun 11

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Jun 11

Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (AUTL), Galmed Pharmaceuticals (GLMD) and Oculis Holding (OCS)

TIPRANKS
·
Jun 11

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Jun 10

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease

GlobeNewswire
·
Jun 09

Oculis Stock Plummets After Phase 3 Trial Failures, Prompting Multiple Law Firm Probes

Deep News
·
Jun 09

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

GlobeNewswire
·
Jun 09

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO) and Oculis Holding (OCS)

TIPRANKS
·
Jun 06

Oculis Holding (OCS) Is Down 60.1% After OCS-01 Trial Failure And Pipeline Pivot – Has The Bull Case Changed?

Simply Wall St.
·
Jun 05